TY - JOUR T1 - Allosteric inhibition of the epidermal growth factor receptor through disruption of transmembrane interactions JF - bioRxiv DO - 10.1101/2022.10.31.514582 SP - 2022.10.31.514582 AU - Jennifer A Rybak AU - Amita R Sahoo AU - Soyeon Kim AU - Robert J Pyron AU - Savannah B Pitts AU - Saffet Guleryuz AU - Adam W Smith AU - Matthias Buck AU - Francisco N Barrera Y1 - 2022/01/01 UR - http://biorxiv.org/content/early/2022/11/01/2022.10.31.514582.abstract N2 - The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase (RTK) commonly targeted for inhibition by anti-cancer therapeutics. Current therapeutics target EGFR’s kinase domain or extracellular region. However, these types of inhibitors are not specific for tumors over healthy tissue and therefore cause undesirable side effects. Our lab has recently developed a new strategy to regulate RTK activity by designing a peptide that specifically binds to the transmembrane (TM) region of the RTK to allosterically modify kinase activity. These peptides are acidity-responsive, allowing them to preferentially target acidic environments like tumors. We have applied this strategy to EGFR and created the PET1 peptide. We observed that PET1 behaves as a pH-responsive peptide that modulates the configuration of the EGFR TM through a direct interaction. Our data indicated that PET1 inhibits EGFR-mediated cell migration. Finally, we investigated the mechanism of inhibition through molecular dynamics simulations, which showed that PET1 sits between the EGFR TM dimer. We propose that the resulting disruption of native TM interactions disrupts the conformation of the kinase domain, inhibiting EGFR’s ability to send migratory cell signals. This study is a proof-of-concept that acidity-responsive membrane peptide ligands can be generally applied to RTKs. In addition, PET1 constitutes a viable approach to therapeutically target the TM of EGFR.Competing Interest StatementThe authors have declared no competing interest. ER -